The Glial Scar Timeline—Reactive Gliosis in StagesSpinal cord injury triggers astrocyte activation within hours. By 24-48 hours, astrocytes begin hypertrophy. The scar forms in phases: initial CSPG deposition (days 3-7), dense matrix assembly (weeks 2-4), and mature scar stabilization (month 2+).The CSPG FamilySix major CSPGs dominate: neurocan, phosphacan, versican, aggrecan, brevican, and decorin. Each has distinct expression patterns and inhibitory potency.Neurocan peaks at day 7 and remains elevated. It binds NCAM, blocking axon extension via contact inhibition. Aggrecan deposits later but creates the most stable barrier. Its sulfated GAG chains form a hydrated gel that physically excludes growth cones.Versican bridges cell-matrix signaling. It binds integrins and CSPG receptors, triggering growth cone collapse.Mechanism—Three PathwaysCSPGs inhibit via:1. Core protein interactions: Phosphacan binds NCAM and L1CAM, disrupting adhesive signaling.2. GAG chains: Sulfated chondroitin sulfate (4S, 6S) activates protein tyrosine phosphatase sigma (PTPσ). This triggers RhoA/ROCK phosphorylation, collapsing growth cone filopodia.3. Masking permissive substrates: CSPG deposition makes laminin and fibronectin inaccessible.Chondroitinase ABC TherapyChABC digests chondroitin sulfate chains, converting CSPGs from inhibitory to permissive substrates. Bradbury et al. (2002) first showed ChABC promotes functional recovery in SCI.Challenges: ChABC is bacterial-derived, thermally unstable, requires intrathecal delivery, and generates immune responses. Davies et al. (2021) developed thermostable variants with enhanced 37°C activity.Timing the Therapeutic WindowEarly scarring (days 3-14) involves loosely organized CSPGs. Mature scars (week 4+) feature stable, cross-linked matrices with reduced plasticity.James et al. (2015) found ChABC in week 1 had limited effect—the scar had not stabilized. Treatment at weeks 3-4 showed maximal axon penetration. Wait until week 8 and the matrix became too dense.Therapeutic window: early enough to prevent chronic stabilization, late enough to avoid hemorrhagic inflammation.Combinatorial StrategiesChABC alone is insufficient. Current pairing includes:- NT-3 gradients attract regenerating axons (Grimpe & Silver 2004)- Minocycline reduces microglial activation from ChABC- Stem cell bridges create axon conduits through digested channelsTargeted DeliveryCartes et al. (2022) developed antibody-targeted ChABC—fused to antibodies against CSPG core proteins. This localizes digestion to scar-specific isoforms, sparing healthy tissue.Clinical TranslationThree approaches in development:1. Direct intrathecal ChABC (Phase I at SCIRC)2. Antibody-targeted delivery (preclinical)3. Small molecule CSPG synthesis inhibitorsThe timing hypothesis: early vs chronic treatment shows different efficacy profiles. CSF CSPG profiling may identify optimal ChABC responders.Key citations: Bradbury et al. (2002) Nature; James et al. (2015) J Neurosci; Davies et al. (2021) Exp Neurol; Cartes et al. (2022) J NeurotraumaAttribution: Research synthesis via literature